BJeLR cell-derived xenograft mice models with prostaglandin-endoperoxide synthase-2 (PTGS-2) upregulation, which is a particular marker for RSL3 and erastin-induced ferroptosis within tumors, were shown to have decreased tumor development when treated with RSL3, which is a ferroptosis-inducing agent [42]. This evidence concerns the gene PTGS2 and neoplasm.